biotech · Non small cell lung cancer · oligometastatic hormone sensitive prostate cancer · CERO
CERo Therapeutics
CERO THERAPEUTICS HOLDINGS, INC.
CERo Therapeutics clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
201 Haskins Way, 230, South San Francisco, California 94080, US HQ
17 Employees
Public company Type
CERO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 201 Haskins Way, 230, South San Francisco, California 94080, US
- Employees
- 17
- Programs
- 47
- Drugs
- 84
- Patents
- 14
CERo Therapeutics projects
2 ClinicalTrials.gov programs sponsored by CERo Therapeutics.
CERo Therapeutics has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
Frequently asked questions
How many clinical projects does CERo Therapeutics have?
2 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.